IONS

SEC source: 0000874015-17-000050 · edgar.xml · derivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 5,904

Underlying: Common Stock · 1,500 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000050 · edgar.xml · derivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,642

Underlying: Common Stock · 15,000 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000050 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,062

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's on 9/21/2015 and 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's on 9/21/2015 and 6/17/2016.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $52.50, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-17-000050 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's on 9/21/2015 and 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's on 9/21/2015 and 6/17/2016.

SEC source: 0000874015-17-000050 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,014

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $52.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-17-000050 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

SEC source: 0000874015-17-000049 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,626

F2 · kind: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014.

F2 · shares: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014.

SEC source: 0000874015-17-000041 · edgar.xml · derivative · entry 4

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Joseph H Wender Trust Dtd

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2027-07-02

F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000041 · edgar.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Joseph H Wender Trust Dtd

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000042 · edgar.xml · derivative · entry 10

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 7,404

Underlying: Common Stock · 1,500 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000042 · edgar.xml · derivative · entry 9

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,642

Underlying: Common Stock · 1,538 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000042 · edgar.xml · derivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,462 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,062

F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.79 to $52.30, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4.

SEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 5

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.

SEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,014

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

SEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,552

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

SEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,014

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.79 to $52.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-17-000042 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.

SEC source: 0000874015-17-000040 · edgar.xml · derivative · entry 5

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2027-07-02

F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000040 · edgar.xml · derivative · entry 4

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000039 · edgar.xml · derivative · entry 4

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600

Underlying: Common Stock · 16,000 shares

Expires 2027-07-02

F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000039 · edgar.xml · derivative · entry 3

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000038 · edgar.xml · derivative · entry 5

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2027-07-02

F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000038 · edgar.xml · derivative · entry 4

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000037 · edgar.xml · derivative · entry 4

Castleman Breaux · CIK 0001335073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2027-07-02

F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000037 · edgar.xml · derivative · entry 3

Castleman Breaux · CIK 0001335073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000036 · edgar.xml · derivative · entry 5

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2027-07-02

F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000036 · edgar.xml · derivative · entry 4

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017.

SEC source: 0000874015-17-000038 · edgar.xml · nonDerivative · entry 1

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-17-000049 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,935

F1 · kind: Reporting 163 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 163 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 163 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 163 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000048 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,741

F1 · kind: Reporting 90 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 90 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 90 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 90 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000047 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,433

F1 · kind: Reporting 134 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 134 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 134 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 134 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000046 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,392

F1 · kind: Reporting 104 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 104 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 104 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 104 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000045 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,158

F1 · kind: Reporting 196 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 196 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 196 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 196 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000043 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,041

F1 · kind: Reporting 253 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July1, 2017. These 253 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 253 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July1, 2017. These 253 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000044 · edgar.xml · nonDerivative · entry 1

Boyce Sarah · CIK 0001629383 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,269

F1 · kind: Reporting 17 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 17 shares may not be sold until January 2, 2018.

F1 · shares: Reporting 17 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 17 shares may not be sold until January 2, 2018.

SEC source: 0000874015-17-000041 · edgar.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Joseph H Wender Trust Dtd

Disclosed balance after: 3,999

Underlying: Common Stock · 2,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-17-000041 · edgar.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Joseph W Wender Trust Dtd

Disclosed balance after: 36,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-17-000040 · edgar.xml · derivative · entry 3

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,999

Underlying: Common Stock · 2,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-17-000040 · edgar.xml · nonDerivative · entry 1

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-17-000039 · edgar.xml · derivative · entry 2

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,936

Underlying: Common Stock · 2,001 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-17-000039 · edgar.xml · nonDerivative · entry 1

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,815

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-17-000038 · edgar.xml · derivative · entry 3

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,999

Underlying: Common Stock · 2,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-17-000037 · edgar.xml · derivative · entry 2

Castleman Breaux · CIK 0001335073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,999

Underlying: Common Stock · 3,406 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-17-000037 · edgar.xml · nonDerivative · entry 1

Castleman Breaux · CIK 0001335073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-17-000036 · edgar.xml · derivative · entry 3

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,999

Underlying: Common Stock · 2,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-17-000036 · edgar.xml · nonDerivative · entry 1

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-17-000034 · edgar.xml · derivative · entry 3

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700

Underlying: Common Stock · 70 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000034 · edgar.xml · nonDerivative · entry 2

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,299

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 1/6/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 1/6/2017.

SEC source: 0000874015-17-000034 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,369

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 1/6/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 1/6/2017.